Sutureless, ultra-swollen hydrogel scleral buckle for microinvasive treatment of rhegmatogenous retinal detachment.
This hydrogel offers a promising alternative to traditional scleral buckling for retinal detachment, but human trials are needed to confirm its clinical applicability.
Where it sits
this study against the rest of the navepegritide corpusSummary and findings
The study developed an ultra-swollen hydrogel scleral buckle for treating rhegmatogenous retinal detachment. The hydrogel swells to 830% of its original volume, eliminating the need for sutures. In vitro and in vivo studies showed biocompatibility and effective retinal reattachment.
Abstract
Rhegmatogenous retinal detachment (RRD) is an ophthalmic emergency requiring prompt treatment to prevent irreversible vision loss or blindness. Although scleral buckling is a commonly used external surgical procedure for RRD, it poses significant challenges, including suture-related complications and implant-associated adverse effects (e.g., foreign-body reaction, scleral indentation, and conjunctival exposure of conventional silicone implants). Herein, we developed an ultra-swollen hydrogel as an alternative scleral buckle to address these limitations. Specifically, this hydrogel was formulated with N-vinylpyrrolidone (NVP) and methacryloxyethyltrimethylammonium chloride (DMC) as hydrophilic components, reinforced with methyl methacrylate (MMA), and crosslinked with N, N'-bis(acryloyl)cystamine (BCA). This formulation enables the hydrogel to be implanted in a dehydrated, compact form through a small incision and subsequently swell in situ to 830% of its original volume for scleral buckling treatment of RRD. Despite this high swelling ratio, the densely crosslinked network (based on BCA crosslinker) preserves sufficient mechanical integrity, and the swollen hydrogel tightly conforms to the extrascleral surface, generating sufficient friction to eliminate the need for sutures and thus avoiding suture-related complications associated with conventional silicone implants. In vitro assessments demonstrated excellent biocompatibility, with no significant cytotoxicity or adverse effects on cell proliferation. Building on this in vitro safety profile, in vivo studies confirmed that the hydrogel provided sufficient external support to facilitate retinal reattachment without inducing significant rejection responses. In summary, this ultra-swollen hydrogel represents a novel and promising therapeutic strategy for RRD, with significant potential for clinical translation.
Background
Rhegmatogenous retinal detachment is a critical condition that can lead to vision loss if not treated promptly. Traditional scleral buckling, while effective, has drawbacks such as suture-related complications and adverse reactions to implants. This study explores a novel hydrogel-based approach to mitigate these issues, potentially offering a less invasive and more biocompatible alternative.
Methods
The study designed a hydrogel with N-vinylpyrrolidone, methacryloxyethyltrimethylammonium chloride, and methyl methacrylate, crosslinked with N, N'-bis(acryloyl)cystamine. The hydrogel was tested in vitro for biocompatibility and in vivo for efficacy in retinal reattachment. The primary outcome was the hydrogel's ability to swell and conform to the scleral surface without sutures.
Results
The hydrogel swelled to 830% of its original volume, maintaining mechanical integrity and conforming to the scleral surface. In vitro tests showed no significant cytotoxicity, and in vivo studies demonstrated effective retinal reattachment without significant rejection responses.
Interpretation
The findings suggest that the hydrogel could be a viable alternative to traditional scleral buckling, potentially reducing complications associated with sutures and implants. However, the lack of human clinical trials limits the ability to generalize these results to clinical practice. Further studies are needed to confirm efficacy and safety in humans.
Key findings
- Hydrogel swells to 830% of its original volume.
- No significant cytotoxicity observed in vitro.
- Hydrogel provides sufficient external support for retinal reattachment.
- No significant rejection responses in vivo.
Limitations
- No human data, only in vitro and in vivo models.
- Potential differences in human tissue response not accounted for.
- Lack of long-term follow-up data.